Clinical trial
A Phase II Trial Involving Patients With Recurrent PCNSL Treated With Carboplatin/BBBD, by Adding Rituxan (Rituximab), An Anti CD-20 Antibody, To The Treatment Regimen
NCT00074165 is registered in ClinicalTrials.gov with OHSU Knight Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial Involving Patients With Recurrent PCNSL Treated With Carboplatin/BBBD, by Adding Rituxan (Rituximab), An Anti CD-20 Antibody, To The Treatment Regimen
- Lead sponsor
- OHSU Knight Cancer Institute
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- January 31, 2003
- Completion date
- December 31, 2010
- Enrollment
- 17 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
brain and central nervous system tumors, drug/agent toxicity by tissue/organ, lymphoma, thrombocytopenia